ArticleCurrent microbiology2025
Isolation of Two Antiviral Compounds from Pelargonium Graveolens Displaying Different Modes of Action.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study explores the remarkable dual antiviral potential of Pelargonium graveolens, an edible aromatic plant widely valued in traditional medicine and culinary applications. The ethanol extract from P. graveolens leaves and its ethyl acetate fraction demonstrated significant inhibitory efficacy against both Herpes Simplex Virus Type 2 (HSV-2) and Coxsackievirus B3 (CVB-3), with notable selectivity index of 134 and 83, respectively. Mechanistic investigations revealed distinct modes of action: the ethanol extract primarily targets viral entry processes and exhibits direct virucidal effects against HSV-2, whereas the ethyl acetate fraction specifically inhibits CVB-3 post-infection. Bioassay-guided fractionation and purification using TLC and HPLC-DAD-ESI-MS
Indexed as
Identifiers
41160253What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.